Experience with tacrolimus in children with steroid-resistant nephrotic syndrome

Lavjay Butani, Rajendra Ramsamooj

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Children with steroid-resistant nephrotic syndrome (SRNS) are at risk of developing renal failure. We report here the results of a single-center retrospective observational study of the remission rate in pediatric patients with SNRS receiving tacrolimus. Serial renal biopsies from children on tacrolimus therapy were evaluated for tubulointerstitial fibrosis and transforming growth factor-β immunostaining. Of the 16 children with SRNS, 15 went into complete remission after a median of 120 days of therapy. Nine children were able to stop steroids, while the others were on tapering doses. Forty-seven percent had relapses, most of which were steroid-responsive. Serial renal biopsies were obtained from seven children after a median treatment duration of 24 months; two of these children had increased tubulointerstitial fibrosis and four showed increased transforming growth factor-β tissue staining. Children with worsening histological findings were younger. There was no significant association between tacrolimus exposure and biopsy changes, although the average trough level was higher in those children with worsening histological findings. In conclusion, tacrolimus may be a safe and effective alternative agent for inducing remission in children with SRNS. However, caution needs to be taken when prescribing this agent due to its narrow therapeutic index. Serial renal biopsies are necessary to check for subclinical nephrotoxicity, especially in younger children and those with higher trough levels.

Original languageEnglish (US)
Pages (from-to)1517-1523
Number of pages7
JournalPediatric Nephrology
Volume24
Issue number8
DOIs
StatePublished - 2009

Fingerprint

Nephrotic Syndrome
Tacrolimus
Steroids
Biopsy
Transforming Growth Factors
Kidney
Fibrosis
Therapeutics
Observational Studies
Renal Insufficiency
Retrospective Studies
Pediatrics
Staining and Labeling
Recurrence

Keywords

  • Calcineurin inhibitor
  • Glomerulonephritis
  • Nephrosis
  • Nephrotoxicity
  • Pediatric

ASJC Scopus subject areas

  • Nephrology
  • Pediatrics, Perinatology, and Child Health

Cite this

Experience with tacrolimus in children with steroid-resistant nephrotic syndrome. / Butani, Lavjay; Ramsamooj, Rajendra.

In: Pediatric Nephrology, Vol. 24, No. 8, 2009, p. 1517-1523.

Research output: Contribution to journalArticle

@article{d884abb7bd7841adba16c7326782beaf,
title = "Experience with tacrolimus in children with steroid-resistant nephrotic syndrome",
abstract = "Children with steroid-resistant nephrotic syndrome (SRNS) are at risk of developing renal failure. We report here the results of a single-center retrospective observational study of the remission rate in pediatric patients with SNRS receiving tacrolimus. Serial renal biopsies from children on tacrolimus therapy were evaluated for tubulointerstitial fibrosis and transforming growth factor-β immunostaining. Of the 16 children with SRNS, 15 went into complete remission after a median of 120 days of therapy. Nine children were able to stop steroids, while the others were on tapering doses. Forty-seven percent had relapses, most of which were steroid-responsive. Serial renal biopsies were obtained from seven children after a median treatment duration of 24 months; two of these children had increased tubulointerstitial fibrosis and four showed increased transforming growth factor-β tissue staining. Children with worsening histological findings were younger. There was no significant association between tacrolimus exposure and biopsy changes, although the average trough level was higher in those children with worsening histological findings. In conclusion, tacrolimus may be a safe and effective alternative agent for inducing remission in children with SRNS. However, caution needs to be taken when prescribing this agent due to its narrow therapeutic index. Serial renal biopsies are necessary to check for subclinical nephrotoxicity, especially in younger children and those with higher trough levels.",
keywords = "Calcineurin inhibitor, Glomerulonephritis, Nephrosis, Nephrotoxicity, Pediatric",
author = "Lavjay Butani and Rajendra Ramsamooj",
year = "2009",
doi = "10.1007/s00467-009-1220-z",
language = "English (US)",
volume = "24",
pages = "1517--1523",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - Experience with tacrolimus in children with steroid-resistant nephrotic syndrome

AU - Butani, Lavjay

AU - Ramsamooj, Rajendra

PY - 2009

Y1 - 2009

N2 - Children with steroid-resistant nephrotic syndrome (SRNS) are at risk of developing renal failure. We report here the results of a single-center retrospective observational study of the remission rate in pediatric patients with SNRS receiving tacrolimus. Serial renal biopsies from children on tacrolimus therapy were evaluated for tubulointerstitial fibrosis and transforming growth factor-β immunostaining. Of the 16 children with SRNS, 15 went into complete remission after a median of 120 days of therapy. Nine children were able to stop steroids, while the others were on tapering doses. Forty-seven percent had relapses, most of which were steroid-responsive. Serial renal biopsies were obtained from seven children after a median treatment duration of 24 months; two of these children had increased tubulointerstitial fibrosis and four showed increased transforming growth factor-β tissue staining. Children with worsening histological findings were younger. There was no significant association between tacrolimus exposure and biopsy changes, although the average trough level was higher in those children with worsening histological findings. In conclusion, tacrolimus may be a safe and effective alternative agent for inducing remission in children with SRNS. However, caution needs to be taken when prescribing this agent due to its narrow therapeutic index. Serial renal biopsies are necessary to check for subclinical nephrotoxicity, especially in younger children and those with higher trough levels.

AB - Children with steroid-resistant nephrotic syndrome (SRNS) are at risk of developing renal failure. We report here the results of a single-center retrospective observational study of the remission rate in pediatric patients with SNRS receiving tacrolimus. Serial renal biopsies from children on tacrolimus therapy were evaluated for tubulointerstitial fibrosis and transforming growth factor-β immunostaining. Of the 16 children with SRNS, 15 went into complete remission after a median of 120 days of therapy. Nine children were able to stop steroids, while the others were on tapering doses. Forty-seven percent had relapses, most of which were steroid-responsive. Serial renal biopsies were obtained from seven children after a median treatment duration of 24 months; two of these children had increased tubulointerstitial fibrosis and four showed increased transforming growth factor-β tissue staining. Children with worsening histological findings were younger. There was no significant association between tacrolimus exposure and biopsy changes, although the average trough level was higher in those children with worsening histological findings. In conclusion, tacrolimus may be a safe and effective alternative agent for inducing remission in children with SRNS. However, caution needs to be taken when prescribing this agent due to its narrow therapeutic index. Serial renal biopsies are necessary to check for subclinical nephrotoxicity, especially in younger children and those with higher trough levels.

KW - Calcineurin inhibitor

KW - Glomerulonephritis

KW - Nephrosis

KW - Nephrotoxicity

KW - Pediatric

UR - http://www.scopus.com/inward/record.url?scp=67649414912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649414912&partnerID=8YFLogxK

U2 - 10.1007/s00467-009-1220-z

DO - 10.1007/s00467-009-1220-z

M3 - Article

C2 - 19499248

AN - SCOPUS:67649414912

VL - 24

SP - 1517

EP - 1523

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 8

ER -